Deletion of Mocos induces xanthinuria with obstructive nephropathy and major metabolic disorders in mice

DOI: 10.34067/KID.0001732021

Delphine Sedda, Claire Mackowiak, Julie Pailoux, Elodie Culerier, Ana Dudas, Pauline Rontani, Nicolas Erard, Antoine Lefevre, Sylvie Mavel, Patrick Emond, Frederic Foucher, Marc Le Bert, Valerie Quesniaux, Michael Mihatsch, Bernhard Ryffel, and Madeleine Erard-Garcia

Key Points:
*A knockout mouse targeting the molybdenum cofactor sulfurase (Mocos) gene develops xanthinuria type II with lethal obstructive nephropathy

*Xanthinuric Mocos KO mice display moderate renal inflammation and fibrosis, normocytic anemia and reduced detoxification defense systems

*Purine, but also amino acids and phospholipids metabolic pathways are altered in Mocos knockout kidneys

Abstract:
Background: Xanthinuria type II is a rare autosomal purine disorder. This recessive defect of purine metabolism remains an underrecognized disorder. Methods: Mice with targeted disruption of the molybdenum cofactor sulfurase (Mocos) gene were generated to enable an integrated understanding of purine disorders and evaluate pathophysiological functions of this gene found in large number of pathways and known to be associated with autism. Results: Mocos deficient mice die with 4 weeks of age due to renal failure of distinct obstructive nephropathy with xanthinuria, xanthine deposits, cystic tubular dilatation, Tamm Horsfall (uromodulin) protein deposits, tubular cell necrosis with neutrophils and occasionally hydronephrosis with urolithiasis. Obstructive nephropathy is associated with moderate interstitial inflammatory and fibrotic responses, anemia, reduced detoxification systems and important alterations of the metabolism of purines, amino acids and phospholipids.Conversely, heterozygous mice expressing reduced MOCOS protein are healthy with no apparent pathology. Conclusions: Mocos deficient mice develop a lethal obstructive nephropathy associated with profound metabolic changes. Studying MOCOS functions may provide important clues about the underlying pathogenesis of xanthinuria and other diseases requiring early diagnosis

Disclosures: All authors have nothing to disclose.

Funding: FEDER:, EX005756 =BIO-TARGETI116-00110366=BIO-TARGET 2015-2018

Author Contributions: Delphine Sedda: Conceptualization; Investigation Claire Mackowiak: Conceptualization; Data curation; Formal analysis; Investigation Julie Pailoux: Conceptualization; Investigation Elodie Culerier: Conceptualization Ana Dudas: Investigation Pauline Rontani: Conceptualization; Investigation Nicolas Erard: Investigation Antoine Lefevre: Conceptualization Sylvie Mavel: Conceptualization; Data curation; Formal analysis Patrick Emond: Data curation; Formal analysis Frederic Foucher: Conceptualization; Data curation Marc Le Bert: Conceptualization Valerie Quesniaux: Project administration Michael Mihatsch: Conceptualization; Data curation; Formal analysis; Investigation; Writing - original draft; Writing - review and editing Bernhard Ryffel: Funding acquisition Madeleine Erard-Garcia: Conceptualization; Data curation; Investigation; Project administration; Supervision; Validation; Writing - original draft; Writing - review and editing

Clinical Trials Registration: No

Registration Number:
How to Cite this article: Delphine Sedda, Claire Mackowiak, Julie Pailloux, Elodie Culerier, Ana Dudas, Pauline Rontani, Nicolas Erard, Antoine Lefevre, Sylvie Mavel, Patrick Emond, Frederic Foucher, Marc Le Bert, Valerie Quesniaux, Michael Mihatsch, Bernhard Ryffel, and Madeleine Erard-García, Deletion of Mocos induces xanthinuria with obstructive nephropathy and major metabolic disorders in mice, Kidney360, Publish Ahead of Print, 10.34067/KID.0001732021
Deletion of Mocos induces xanthinuria with obstructive nephropathy and major metabolic disorders in mice

Delphine Sedda¹, Claire Mackowiak¹, Julie Pailloux¹, Elodie Culerier¹, Ana Dudas¹, Pauline Rontani², Nicolas Erard², Antoine Lefevre³, Sylvie Mavel³, Patrick Emond³,⁴,⁵, Frederic Foucher⁶, Marc Le Bert¹, Valerie FJ Quesniaux¹, Michael J. Mihatsch⁷, Bernhard Ryffel¹ and Madeleine Erard-Garcia¹

¹Experimental and Molecular Immunology and Neurogenetics (INEM), Orleans University, CNRS UMR7355, Orleans, France.
²Institut of NeuroPhysiopathology (INP), Aix-Marseille University, CNRS UMR7051, Marseille, France.
³iBrain, Tours University, Inserm UMR 1253, Tours, France.
⁴Division of In Vitro Nuclear Medecine, Regional University Hospital of Tours, France.
⁵PST Analysis of Biological Systems, Tours University, France.
⁶Center for Molecular Biophysics (CBM), CNRS UPR4301, Orléans, France.
⁷Institute for Pathology, University Hospital of Basel, Basel, Switzerland.

Correspondence to :
Madeleine Erard-Garcia
CNRS - UMR 7355 - INEM
3B, rue de la Férollerie
45071 Orléans cedex 2
FRANCE
Tél: +33 2 38 25 79 70
E-mail madeleine.erard@cnrs-orleans.fr
Key points

- A knockout mouse targeting the molybdenum cofactor sulfatase (*Mocos*) gene develops xanthinuria type II with lethal obstructive nephropathy.
- Xanthinuric *Mocos* KO mice display moderate renal inflammation and fibrosis, normocytic anemia and reduced detoxification defense systems.
- Purine, but also amino acids and phospholipids metabolic pathways are altered in *Mocos* knockout kidneys.

Abstract

**Background:** Xanthinuria type II is a rare autosomal purine disorder. This recessive defect of purine metabolism remains an underrecognized disorder.

**Methods:** Mice with targeted disruption of the molybdenum cofactor sulfatase (*Mocos*) gene were generated to enable an integrated understanding of purine disorders and evaluate pathophysiological functions of this gene found in large number of pathways and known to be associated with autism.

**Results:** *Mocos* deficient mice die with 4 weeks of age due to renal failure of distinct obstructive nephropathy with xanthinuria, xanthine deposits, cystic tubular dilatation, Tamm Horsfall (uromodulin) protein deposits, tubular cell necrosis with neutrophils and occasionally hydronephrosis with urolithiasis. Obstructive nephropathy is associated with moderate interstitial inflammatory and fibrotic responses, anemia, reduced detoxification systems and important alterations of the metabolism of purines, amino acids and phospholipids. Conversely, heterozygous mice expressing reduced MOCOS protein are healthy with no apparent pathology.
Conclusions: *Mocos* deficient mice develop a lethal obstructive nephropathy associated with profound metabolic changes. Studying MOCOS functions may provide important clues about the underlying pathogenesis of xanthinuria and other diseases requiring early diagnosis.
**Introduction**

Xanthinuria is rare hereditary disorder of purine metabolism. Two forms can be distinguished: namely classic xanthinuria type I, caused by xanthine dehydrogenase (XDH) deficiency alone and xanthinuria type II, caused by the dual deficiency of XDH and aldehyde oxidase1 (AOX1), two enzymes whose activity depends on the presence of molybdenum cofactor sulfurase (MOCOS). Both forms are autosomal recessive disorders displaying identical clinical phenotypes. In about two-thirds of affected individuals, xanthinuria remains an asymptomatic metabolic abnormality throughout life. In the remaining one-third, xanthine stones form and lead to varying degrees of nephrolithiasis, hydronephrosis, and, in some cases, renal failure\(^1\). Clinically, both forms are characterized by marked depletion of uric acid, accumulation of xanthine in blood and urine. Other less common manifestations linked to xanthine deposits may develop such as myositis, arthropathy and duodenal ulcer\(^2\). The differential diagnosis between type I and type II classical xanthinuria relies on a detailed medical history and allopurinol response in hypouremic patients with xanthinuric type II patients failing to metabolize allopurinol into oxypurinol\(^3\).

To date, the true incidence and prevalence of classic xanthinuria is not known because it is rarely reported and often not recognized and underexplored. In this context, only few cases of xanthinuria type II caused by point mutations in the coding sequence of *MOCOS* have been reported in human\(^4\)-\(^9\). *MOCOS* encodes a ubiquitous enzyme that catalyzes the insertion of a terminal sulfur ligand onto MOCO, the molybdenum cofactor, converting the oxo form of MOCO into a sulfurated form\(^10\). The structure of the mammalian MOCOS is similar to ABA3, its plant homologue: it is a two-domain protein containing an N-terminal domain showing homologies to L-cysteine desulfurase and a C-terminal domain able to bind the molybdenum cofactor MOCO\(^11\)-\(^13\). After sulfuration by MOCOS, sulfurated-MOCO is required to activate XDH and AOX1, two structurally complex oxidoreductases. XDH is a rate-limiting enzyme in
the oxidative metabolism of purines: it allows the conversion of hypoxanthine and xanthine to uric acid as well as the oxidation of allopurinol to oxypurinol. XDH is thought to play a key role in a variety of physiological but also pathophysiological conditions such as ischemia–reperfusion injury, endothelial dysfunction, diabetes mellitus but also cardiovascular diseases, renal failure and cancer. It is also a significant component of innate inflammatory signaling and a major source of reactive oxygen species (ROS). Conversely, little is known about the physiological relevance of AOX1, except that it catalyzes the oxidation of several aldehydes to their cognate acids. As XDH, AOX1 is a critical source of ROS and nitric oxide (NO) and it is increasingly recognized as a major contributing factor to drug metabolism and as a source of ROS possibly involved in human pathology.

No study on the potential impact of MOCOS deletion on kidney function and the mechanism by which such mutation could contribute to xanthinuria have been performed. In addition, MOCOS alterations may cause genetic damage of their own and orchestrate a wide variety of clinical syndromes. MOCOS deficiency might be regarded as a risk factor in autism spectrum disorders (ASD), disrupting oxidative stress response and synaptogenesis in neurons derived from human induced-pluripotent stem cells. While these results indicate that MOCOS serves important functions in tissue homeostasis and during neuronal development, the reasons for the wide range of pathophysiological phenotypes observed in MOCOS deficiencies are unclear. To gain insights into the role of MOCOS in purine metabolism and yet unidentified pathways, we have analyzed a new mouse model knockout for Mocos.

We show here that Mocos KO mice die within 4 weeks with xanthinuria and renal failure. While heterozygous Mocos mice grow normally into apparently healthy fertile adults, Mocos KO mice develop obstructive nephropathy with xanthine deposits. In xanthinuric mice, reduced antioxidant defense systems along with anemia may also be involved in the progression of renal injury. Finally, consistent with a role of MOCOS in various signaling pathways, we also report
major differences of metabolism between kidneys of *Mocos* KO and littermate wild type mice, which are related to purine but also amino acids and phospholipids metabolic pathways. These observations suggest that, in addition to its role in purine metabolism leading to obstructive nephropathy, MOCOS deficiency unveils yet unknown functions in other metabolic processes.
Methods

**Generation of Mocos\textsuperscript{em2(ImPC)ics} knockout mice and animal matings**

The CRISPR/Cas9 system was used to generate mice with complete *Mocos* knockout by zygotic injection of CAS9 and multiple adjacent single-guide RNAs (sgRNAs) that target exon 3. Genome editing was performed at PHENOMIN-Mouse Clinical Institute (ICS, Strasbourg-France). The conditions used at ICS to generate the *Mocos* KO via CRISPR/Cas9 approach, can be found in the ICS website (http://www.ics-mci.fr/).

PHENOMIN projects has received an approval from ethic committees and an authorization from the Ministry of Research (France). Project evaluation was realized following the 3Rs and HBA concepts with a huge attention on refinement (use of anesthesia, of painkillers when needed, respect of good practices).

Specific primer sequences used for genotyping were as follow:

*Mocos* For: GGGGATTGTTGTATTGTGCCTGTCTG

*Mocos* Rev: CTTGCCCTCTGTCTTCTGACCTGAGG.

*Mocos* KO mice were obtained by crossing heterozygous mice for the gene *Mocos*. Experiments were performed with 4 to 10 week-old female or male mice. All *Mocos*-deficient mice and WT littermate controls (C57BL/6J background) were bred and housed in our specific pathogen-free animal facility at TAAM (Transgenesis, Archiving and Animal Models, TAAM-UPS 44, CNRS, Orleans, France) under agreement D-45-234-6, 2014. Mice were maintained in a temperature-controlled (23°C) facility with strict 12-hour light/dark cycles and given free access to food and water. Animal experiments were performed according to the French Institutional Committee under agreement CLE CCO 2017-1134.

**Hematology and urine analysis**
Blood was collected in EDTA tubes (Sarstedt 20.1341.100) and read with analyzer SCIL vet abc+. Before use, serum was collected in microvette gel tubes (Sarstedt 20.1344) and centrifuge 10000g for 5 min. The Xanthine/Hypoxanthine levels were determined using the Xanthine/Hypoxanthine Assay kit (Abcam, ab155900) following manufacturer's protocol. Urine was freshly collected and pH was determined with pH indicator paper (Whatman, 2600 108).

**Histological and Immunofluorescence Analysis**

Dissected tissues were fixed in 4% buffered paraformaldehyde and paraffin embedded under standard conditions. Tissue sections (3µm) were stained with hematoxylin–eosin (HE) and special stains according to standard laboratory procedures. Immunohistochemistry for uromodulin/Tamm Horsfall Protein was performed according to standard procedures (https://esp-nephropathology-working-group.org/technical-notes/) with a mouse monoclonal antibody purchased from Cedarlane.

For Immunofluorescence, tissues were fixed for 3 days in 4% PFA and submerged in 20% sucrose for 1 week. They were then embedded in OCT (Tissue-Teck) and 10 µM sections were prepared with cryotome (Leica). TUNEL staining was performed on sections using the ApopTag® Fluorescein In Situ Apoptosis Detection kit (Merck, S7110) following manufacturer's protocol. For Ki67 (PCNA) staining, slides were incubated 30 min in citrate buffer at 80 °C, washed in TBS-Tween and then incubated overnight with rabbit-anti-mouse-Ki67 (Abcam, 4 µg/ml, ab15580). After washing slides were treated with 0,05% pontamin sky blue (Sigma) for 15 min and then incubated with secondary goat anti-rabbit antibody (Abcam, 2µg/mL, ab150077) for 45 min at room temperature. After washing, slides were incubated with DAPI (Fisher Scientific) and mounted in fluoromount® (SouthernBiotech). Tissue sections
were analysed on a Leica fluorescence microscope Leica (Leica, CTR6000) at x200 magnification. The slides were analyzed and semi-quantitatively scored.

**RNA preparation, PCR and qPCR**

Total RNA was extracted using TRI-Reagent (Sigma) according to the manufacturer’s instruction. RNA integrity and quality were controlled using Agilent RNA 6000 Nanopuces kit®. Reverse transcription was performed with SuperScript®III Kit (Invitrogen), and the resultant cDNAs were quantitatively amplified with real-time-PCR using QuantiTect® Primer Assay kit (Qiagen) and GoTaq® qPCR-Master Mix (Promega). RNA expression was normalized to TBP (TATA-Binding Protein) expression and data were analyzed using the comparative analysis of relative expression by \( \Delta\Delta^Ct \) methods. Primers sequences are reported in Supplemental Table 1.

**Western blot**

Protein concentrations were quantified using the Bio-Rad DCTM protein assay kit following manufacturer’s instructions. After blocking, membranes were probed with rabbit anti-MOCOS (Novus biologicals, NBP2-14243, 1/100), rabbit anti AKR1C1 (GeneTex 105620, 1/1000) or mouse anti-β-Actin (Sigma-Aldrich, A2228, 1/5000) antibodies. After overnight incubation at 4°C, the appropriate horseradish peroxidase-conjugated secondary IgG antibodies were added for 2 hours at room temperature. Signals were quantified using ImageJ software.

**Metabolic analysis**

Metabolic analyses were performed by liquid chromatography coupled with high resolution mass spectrometry (LC-HRMS) based on standard metabolomics approaches. Briefly, frozen kidney tissue samples were lyophilized during 48 h and milled to a fine powder. Two
milligrams of ground samples were extracted with 1.5 mL of Methanol/milliQ water (1/1). After centrifugation, the supernatants were collected and concentrated at 35°C for 2h30. The analyses were done on a UPLC Ultimate 3000 system (Dionex), coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Germany) and operated in positive (ESI+) and negative (ESI−) electro spray ionization modes. Chromatography was carried out with a Phenomenex Kinetex 1.7mXB C18 (150mm×2.10mm) and 100Å UHPLC column. The solvent system comprised mobile phase A [0.1% (vol/vol) formic acid in water], and mobile phase. Data were processed using Xcalibur® software (Thermo Fisher Scientific, San Jose, CA). A library of standard compounds (Mass Spectroscopy Metabolite Library of Standards MSMLS supplied by IROA TechnologiesTM) were analyzed with the same conditions and gradient of mobile phases than those used to analyze the extracted metabolites. For data processing, briefly, peaks with greater than 30% variance (CV %) in quality control samples were removed. The normalization was done to the total area of the peaks of interest. The multivariate analyses were done using Simca-P+15 software (Umetrics, Umeå, Sweden) as previously described25. Briefly, the data analyses were first conducted using principal component analysis (PCA) to detect outliers. Discriminant metabolites were obtained after orthogonal partial least squares discriminant analysis (OPLS-DA), after elimination of metabolites with low impact in the separation of the different groups. The listing of discriminant metabolites [very important in projection (VIP)] is given in supplemental Table 2. Univariate analyses were performed as non-parametric tests (Wilcoxon rank-sum test) using the web free server Metaboanalyst52 (https://www.metaboanalyst.ca/) with an FDR adjusted p-value of 0.05.

Statistical analysis

All values were presented in the form of mean±SEM. Statistical evaluation of differences between the experimental groups was done by Mann-Whitney non-parametric test, or Log Rank
test for survival. All tests were performed with GraphPad Prism [GraphPad Software Inc., San Diego, CA, USA; www.graphpad.com]. A \( P \)-value <0.05 was considered significant and symbolized with *, ** for \( P < 0.01 \) and *** for \( P < 0.001 \).

Results

**Mice containing a null mutation of Mocos induces a partial lethal phenotype and die prematurely**

To characterize the physiological role of *Mocos*, mice with a targeted disruption in the *Mocos* locus were generated using CRISPR/Cas9 genome editing technology (Figure 1A). After validation of the deletion by sequencing, a significant reduction of *Mocos* mRNA and MOCOS protein levels further confirmed targeting of the gene in engineered mice. Transcript level and protein concentration were reduced to roughly half in heterozygous *Mocos*+/- mice (Figure 1B and C).

Mice homozygous for the disrupted Mocos gene were born phenotypically normal (Figure 1D) but only few mice were recovered at weaning, pointing toward late embryonic or perinatal lethality. Further analysis showed that there was an increased frequency of dead pups after birth although the exact frequency cannot be determined due to cannibalization by the mother. These findings indicate a high perinatal mortality of homozygous pups. Young *Mocos*−/− mice were easily recognized from littermate controls after the first two weeks of life when they stopped gaining weight (Figure 1E, F). Shortly after, all *Mocos* KO mice died between 3 to 8 weeks of age with an average lifespan of 28.4 days (Figure 1G, H). In contrast, heterozygous mice were not different from wild type mice derived from heterozygous breeding pairs; the mice survived and developed normally into apparently healthy fertile adults (Supplemental Figure 1A). These observations indicated that *Mocos* deficiency in mouse leads to a lethal
phenotype with incomplete penetrance and premature death. Because of the runted appearance of the *Mocos* KO mice, all subsequent analyses were conducted on *Mocos* KO mice before death between 3 and 4 weeks of age. In addition, a close monitoring of heterozygous mice for possible signs of disease was prolonged in adult animals ranging from 2 to 20 months of age.

**Inactivation of Mocos causes abnormal morphological features**

At 4 weeks of age, *Mocos* deficient mice displayed major morphologic abnormalities with significant reductions in kidney/ and liver/body weight ratios (33% and 20% reduction respectively) and a substantial increase in brain/body weight ratios (51% increase) when compared to organ/body weight sizes of littermate controls (Supplemental Figure 1B-E). No significant differences in the size or gross morphology in all other organs including lung, spleen or intestine were observed (Supplemental Figure 1F-H). In contrast, *Mocos* heterozygotes showed normal proportions of all organs except the liver which showed a 21% reduction in liver/body weight size when compared to young wild type mice (Supplemental Figure 1B-H).

**Mocos KO mice develop obstructive nephropathy**

Anatomical examination of *Mocos*−/− mice revealed that all internal organs appeared grossly normal with the exception of the kidneys. Macroscopically, the mutation produces profound modifications of the renal structure: kidneys were pale, reduced in size with an irregular surface, while heterozygous *Mocos*+/− mice and wild type littermates appeared normal (Supplemental Figure 1B-C). At low power magnification, the histological evaluation of *Mocos* KO kidneys displayed three major lesions: i) cystic dilatation of tubules mainly in the cortex and less in the medulla (Figure 2A), ii) intra-tubular deposits of round lamellate deposits of Tamm-Horsfall protein with occasionally embedded crystals (empty crystal clefts, Figure 2C-D) and iii) Tamm Horsfall protein deposits in the renal pelvis with damage of the urothelium,
accompanied by inflammation in the surrounding tissue. In the dilated and non-dilated collecting ducts, round lamellate deposits of Tamm-Horsfall protein are present (Figure 2C). These deposits often display a basophilic rim - suggestive of calcification - but give a negative Kossa staining and no birefringent crystals are found after paraformaldehyde fixation. Few empty crystal clefts are, however, present (Figure 2C). The adjacent epithelium is flattened or necrotic with intraluminal cell debris shed with neutrophils and a few multinucleated giant cells are surrounding the deposits (Figure 2C). The interstitial space is slightly oedematous and, adjacent to dilated collecting ducts, cortical areas display tubular atrophy, interstitial fibrosis and mononuclear cell infiltrates (predominately in the subcapsular area) (Figure 2B-D). Primary lesions in glomeruli and vessels are not found. In areas of tubular atrophy, the glomeruli lie close together, vary in size, have collapsed capillary loops and are very rarely sclerotic. Moreover, some deposits of Tamm Horsfall protein, similar to those present in the collecting ducts, are also found in the renal pelvis. These deposits are adhering to the urothelium, giving rise to urothelial damage and loss. Outside the renal pelvis inflammatory infiltrates are seen (Figure 2D).

Occasionally, in about 5% of Mocos KO mice, stones are found in the pelvis and may lead to ureteral obstruction. This obstruction was mostly unilateral and kidneys were displaying a pale and swollen appearance. The histological examination of these enlarged kidneys showed a uniformly thin atrophic renal cortex and a marked dilation of the renal pelvis, characteristic of hydronephrosis (Supplemental Figure 2), while the contra-lateral kidney was small with obstructive nephropathy. Of note, heterozygous mice with partial loss of Mocos expression did not disturb the histology of other organs in young mice or later in adult mice (Supplemental Figure 3).

**Inactivation of Mocos induces xanthinuria**
Because stones sometimes clearly visible to the naked eye and large enough to interfere with normal urinary function were frequently observed in urine and kidneys from affected Mocos mice (Figure 3A), we next analyzed the effects of urinary tract obstruction in biological fluids. Consistent with a role of Mocos in purine metabolism, the colorless and acidic urine (Figure 3B), but also the serum collected from Mocos\textsuperscript{−/−} mice had high levels of xanthine and hypoxanthine as compared with age-matched controls (Figure 3C, D). Kidney stones were composed of xanthine based on their unique Raman spectral fingerprints (Figure 3E, F). The present morphological and biochemical data thus strongly suggest that accumulation of xanthine crystals leads to intra- and extra-renal obstructive nephropathy in Mocos KO mice. Xanthine stones with hydronephrosis are found in mice as well as in hereditary xanthinuria type II in human which is typical crystallopathy, but the prevailing feature in the Mocos KO mouse model is an obstructive nephropathy.

**Renal failure in Mocos KO mice**

Kidney dysfunction in Mocos deficient mice was further evaluated by monitoring biochemical markers for the diagnosis of the progression of kidney damage. Our data denote profound metabolic changes, including drastic increases of serum creatinine and urea in Mocos\textsuperscript{−/−} mice when compared to controls (Figure 4A, B). As expected from the essential role of Mocos in XDH activity, Mocos KO mice had an almost undetectable level of uric acid (Figure 4C). In addition, the serum levels of some hepatic enzymes were altered with a reduced level of alanine aminotransferase (ALAT) and an increased level of alkaline phosphatase (ALP) in Mocos deficient mice (Figure 4D-F), which were not observed in heterozygous Mocos animals when compared to wild type mice at 4 weeks of age or later in adult mice (Supplemental Figure 4A-F). Altogether, these data suggested that the physiopathological changes produced by the complete inactivation of Mocos caused acute renal failure.
**Mocos KO mice display anemia**

Because hematological parameters are tightly regulated traits with high clinical relevance, we also analyzed the haematogram of Mocos−/− and control mice. When compared to littermate controls, Mocos KO mice tend to have almost normal distribution of total white blood cells (WBC) counts (Figure 5). The differential cell counts to identify leukocytes were within the normal range as was the number of platelet. This result excluded a systemic inflammation but it also underscored the presence of mild anemia with reduced circulating red blood cells (RBC) and red cell parameters values outside normal ranges. Of note, hemoglobin and hematocrit values in Mocos−/− mice were significantly decreased compared with that in wild type mice (Figure 5). These disturbances, accompanied by normal values of mean corpuscular volume and mean corpuscular hemoglobin concentration were suggestive of normocytic anemia, a feature frequently associated with poor outcomes in acute and chronic renal failure. On the contrary, heterozygous Mocos mice showed normal haematological parameters at 4 weeks of age and even later (Supplemental Figure 5).

**Mocos KO mice display increased expression of adipogenesis-related genes, and markers of inflammation and fibrosis**

We further investigated dysregulation of lipid metabolism and found enhanced expression of two important regulators of lipid homeostasis, namely CCAAT/enhancer-binding protein-β (C/EBP-β) and peroxisome proliferator activated receptorγ (PPARγ) in Mocos KO mice compared with age-matched counterparts (Figure 6A). This altered lipid signaling network could contribute to the pathophysiology of xanthinuria and interfere with immune regulation because we observed a marked increase in mRNA expression of the proinflammatory factors tumor necrosis factor α (TNF-α) and monocyte chemoattractant protein1 (MCP1/CCL2).
(Figure 6B). Finally, the significant activation of transforming growth factor β1 (TGFβ1), may contribute to renal interstitial fibrosis 27, 28, and serpine 1, the main suppressor of the fibrinolytic system, suggesting a vicious cycle of immune-metabolic dysregulation could promote renal fibrotic responses and kidney dysfunction in Mocos+/− kidneys (Figure 6C). Immunofluorescence imaging ultimately supported visual evidence for tubular damage and repair with increased Apoptag staining (Figure 6D) accompanied by increased fluorescence signal of the proliferating cell marker Ki67 in Mocos+/− kidneys (Figure 6E, F). No sign of inflammation or fibrosis was detected in kidneys of heterozygous Mocos and wild type littermates at 4 weeks of age.

**Impaired ability of xanthinuric animals to mount the biological response to overcome oxidative stress and inflammation**

Because PPARγ plays additional roles by participating in inflammation and oxidative stress in renal disease, we next examined redox homeostasis in Mocos+/− mice. Confirming further the potential antioxidative protective effect of PPARγ29 (Figure 6A), we found that NOX4, a NADPH oxidase isoform expressed in proximal tubular cells and known to be an important source of ROS30, was significantly underexpressed in Mocos+/− kidney when compared to littermate controls (Figure 7A). These possible renoprotective effects of NOX4 and PPARγ were accompanied by increased expression of glutamate-cysteine ligase (GCLC, the key enzyme in glutathione synthesis), but impaired activation of genes encoding many antioxidant and detoxifying enzymes known to be targets of PPAR γ and nuclear factor-erythroid-2-related factor 2 (Nrf2) (Figure 7B-F). Particularly noteworthy was the dysregulation of the thioredoxin (TXN)-based antioxidant system with the significant increase of thioredoxin-inhibitory protein (TXNIP) and thioredoxin-domain containing 12 (TXNDC12) which suggested a disruption of
the TXNIP-TXN complex and endoplasmic reticulum (ER) stress in \( Mocos^{+/} \) kidneys (Figure 7G-I and reference \(^3\)). Finally, our data highlighted the importance of reactive carbonyl species (RCS) stress in affected \( Mocos^{+/} \) kidneys expressing aberrant levels of AKR1B8 and AKR1C1, two members of the aldo-keto reductase (AKR) superfamily involved in detoxification of cytotoxic carbonyls and balance of electrolytes and potassium respectively (Figure 7J-K).

**Major dysfunctions of purine, aminoacids and phospholipids pathways in kidneys from xanthinuric \( Mocos \) mice**

A metabolomics approach was next performed by liquid chromatography tandem high-resolution mass spectrometry method (LC-HRMS) to uncover altered metabolites and biological pathways in \( Mocos^{+/} \) kidneys. As illustrated in Figure 8 and Supplementary Table S1, no significant modification of metabolites was observed in kidney tissues from \( Mocos^{+/} \) mice compared with wild type mice. Conversely, \( Mocos^{+/} \) kidneys revealed significant metabolic perturbations: of the 121 robust metabolites analyzed, 40 metabolites were altered when compared with wild type mice and 31 metabolites showed perturbation of renal expression when the three \( Mocos^{+/+} \), \( Mocos^{+/} \) and \( Mocos^{+/} \) kidney groups were compared (Figure 8 and Supplemental Figure 6). As expected, lack of \( MOCOS \) activity resulted in very low levels of uric acid and allantoin, the primary product of urate oxidation (Figure 8). In this pathway, xanthine and its distant precursors, such as inosine and adenine, were also affected. This result thus reinforced the finding that the main metabolic function of \( Mocos \) is restrained to the purine catabolism pathway. In parallel, in agreement with the role of \( Mocos \) in a physiological alternative to the "classic" pathway of NO formation from L-arginine, the integrity of the arginine-NO/urea system was also disturbed in \( Mocos^{+/} \) kidneys with a strong perturbation of citrulline and guanidoacetic acid (a precursor of creatine), two known
metabolites of the urea cycle (Table 1). Interestingly, Table 1 also highlights significantly altered metabolites involved in energy metabolism and mitochondrial function, such as trimethylammoniobutanoic acid, while the decreased cysteine metabolism might further denote oxidative damage in Mocos KO kidneys. Finally, other notably disturbed metabolic pathways include the phospholipid biosynthetic pathway indicative of massive membrane remodeling of renal cells and the serotonin pathway (5-hydroxyindole acetate) of tryptophan metabolism (Figure 8, Table 1 and Supplemental Table 2).

In summary, the metabolic analysis of Mocos⁻/⁻ kidneys underscored the essential role of purines and highlighted the potential pathophysiological implications of the deregulation of amino acids (3 pathways) and phospholipids metabolisms (2 pathways) in kidneys of Mocos-deficient mice (Supplemental Figure 7).

Discussion

Xanthinuria is an underrecognized disorder that, in less than half of the affected people, is characterized by xanthine stones. This rare genetic disorder may be accompanied by hydronephrosis and eventually other complications of urolithiasis such as pyelonephritis. In our Mocos deficient mouse model of xanthinuria, the leading pathology is obstructive nephropathy. To our knowledge, such a pathology has not been reported in either type I or type II xanthinuria in human. Nonetheless, the Mocos mouse may serve as a model to study the pathogenesis of obstructive nephropathy. Remarkably, the signs of obstructive nephropathy found in Mocos KO mice do not differ from those reported in humans affected by other forms of obstructive nephropathies of variable etiology such as nephrocalcinosis following hyperphosphaturia or hypercalciuria, calcium oxalate nephropathy, urate nephropathy, myeloma kidney, or obstruction following drug crystals. Recently, an attempt to classify crystal nephropathies was
proposed according to the localization of crystal deposits in the renal vasculature (type 1), the nephron (type 2) or the draining urinary tract (type 3)\textsuperscript{33}. Regarding this classification, analysis of the morphological data of \textit{Mocos} deficient mice suggests a prevalence of type 2 and a minor contribution of type 3 nephropathy.

The mechanisms of xanthine crystal precipitation are not resolved but may involve neutrophils interstitial and tubular inflammation with inflammatory cytokines together with precipitation of Tamm Horsfall proteins. Different crystals cause injury in numerous disorders and induce inflammation via the NLRP3 inflammasome and cell death\textsuperscript{34}. In this study, Mulay et al found that crystals of calcium oxalate, monosodium urate, calcium pyrophosphate dihydrate and cystine may trigger caspase-independent cell death via TNF-\textit{α}/TNFR1, RIPK1, RIPK3 and MLKL and initiate tissue injury and organ failure. However, tissue damage and inflammation induced by xanthine crystals have not been reported so far. In view of the tubular cell necrosis and interstitial inflammation in \textit{Mocos} KO mice, activation of the inflammasome or other danger signal pathways are likely activated, causing inflammation. These pathways, including DNA sensing pathways, need further investigation to understanding the molecular mechanisms behind the cellular processes that contribute to the onset and development of the disease. To explain how \textit{Mocos} deletion may cause xanthinuria type II, we suggest a two-step process involving i) an obstructive nephropathy due to production, poor solubility and intratubular precipitation of xanthine and ii) cell stress and death mediated by altered detoxification circuitry, impairment of nutrient delivery and waste product removal from kidney cells. The cellular stress elicited by these events causes inflammation triggering crystal formation, which may then enhance renal pathology.

In the \textit{Mocos} deficient mouse model of obstructive nephropathy, renal stones and decreased renal function are associated with hypouricemia and altered detoxification circuitry. While xanthine stones may be proinflammatory and worsen renal function, several studies have
reported positive correlations between hyperuricemia, kidney inflammation and renal failure induced by urate crystal formation\textsuperscript{35,36}. However, hypouricemia caused by increased excretion or diminished reabsorption of filtered uric acid is also observed in human\textsuperscript{37} and it is established that uric acid is the most abundant soluble antioxidant preserving endothelial function in situations of oxidative stress\textsuperscript{38}. Inflammation and oxidative stress are known to be involved in the pathogenesis of chronic kidney disease in humans and in chronic renal failure in animal models. As far as kidney stone disease is concerned, particularly calcium oxalate, injury induced by high concentrations of oxalate in renal tubular epithelial cells is related to oxidative stress, tissue inflammation and mitochondrial dysfunction\textsuperscript{39}. Our data show disruption of intrarenal redox homeostasis and are consistent with the essential role of MOCOS in aldehyde detoxification\textsuperscript{19,20} and the relevance of RCS metabolism in ROS-related renal injury\textsuperscript{40,41}. They point to the poor ability of xanthinuric animals to mount a protective response to overcome oxidative stress via inflammation.

Metabolomics studies allowed the differential diagnosis of type I and type II classical xanthinuria. These studies have highlighted the role of the purine degradation pathway but also pathways involved in amino acid metabolism (such as tryptophan), vitamin B6, nicotinamide and possibly polyamine catabolism in patients with xanthinuria type II. Severe symptoms are rarely observed in patients with classical xanthinuria presenting usually mild signs. Despite conservation of purine metabolism, the significant differences between mice and man likely reflect divergent features of key stages of kidney development. Moreover, the level of uric acid in mice is lower than that in human because uricase, an enzyme present in mouse but not in human, degrades uric acid into allantoin. Thus, decreased XDH and uric acid levels in the immediate post-natal period in \textit{Mocos} deficient mice may significantly affect renal development and amplify xanthinuria. Although neonatal Mocos KO mice cannot overcome
MOCOS deficiency, we assume that the 50% reduction of MOCOS expression in heterozygous mice might be sufficient for a normal renal and metabolic function in young and aged mice.

Beside its role in nephropathology, MOCOS is involved in complex disorders such as ASD\textsuperscript{20-22}. Although metabolomic studies on complex disorders are far from definitive and unambiguous, analysis of the metabolome has shown great potential to uncover biomarkers for complex diseases such as ASD. Indeed, recent studies on urine from ASD patients have reported that several metabolic profiles associated with amino acids, purine metabolism, creatine metabolism, energy metabolism and oxidative stress could be involved in ASD\textsuperscript{42,43}.

In conclusion, the \textit{Mocos} mouse model may enable an integrated understanding of of xanthinuric obstructive nephropathy and of common mechanisms underlying complex diseases such as metabolic disorders and ASD.
Disclosure
All authors have nothing to disclose.

Funding
This work was supported by CNRS, INSERM, University of Orleans, University of Tours and the European funding in Region Centre-Val de Loire (FEDER N°2016-00110366=BIO-TARGET 2015-2018 and FEDER N° EX005756 =BIO-TARGETII).

Acknowledgments
We would like to thank PHENOMIN and the Mouse Clinical Institute (ICS, Strasbourg, France) for the generation of Mocos KO mice. Our special thanks are going to François Erard and to Melody Thilloux and Mathilde Favrat for technical assistance and animal handling. We are also grateful to the Center for Typing and Archiving of Animal Models (TAAM, Orleans, France) and more specifically to Emilie Bouvier and Severine Grieszmann for taking care of the animals. We also thank the department “Analyse des Systemes Biologiques” (PST ASB, Universite de Tours, France) for their help with sample analyses.

Author contributions
Delphine Sedda: Conceptualization; Investigation. Claire Mackowiak: Conceptualization; Data curation; Formal analysis; Investigation. Julie Pailloux: Conceptualization; Investigation. Elodie Culerier: Conceptualization. Ana Dudas: Investigation. Pauline Rontani: Conceptualization; Investigation. Nicolas Erard: Investigation. Antoine Lefevre: Conceptualization. Sylvie Mavel: Conceptualization; Data curation; Formal analysis. Patrick Emond: Data curation; Formal analysis. Frederic Foucher: Conceptualization; Data curation. Marc Le Bert: Conceptualization. Valerie Quesniaux: Project administration. Michael Mihatsch: Conceptualization; Data curation; Formal analysis; Investigation; Writing - original draft; Writing - review and editing. Bernhard Ryfferl: Funding acquisition. Madeleine Erard-Garcia: Conceptualization; Data curation; Investigation; Project administration; Supervision; Validation; Writing - original draft; Writing - review and editing.
Supplemental material Table of Contents:

Supplemental Methods

Legends of Supplemental Figures

Supplemental Figure 1

Supplemental Figure 2

Supplemental Figure 3

Supplemental Figure 4

Supplemental Figure 5

Supplemental Figure 6

Supplemental Figure 7

Supplemental Table 1

Supplemental Table 2
References


**Table 1:** List of the top six main disturbed pathways, and the related dysregulated metabolites in kidneys from the 3 groups of mice (*Mocos*<sup>+/+</sup>, *Mocos*<sup>+/−</sup> and *Mocos*<sup>−/−</sup> mice).

<table>
<thead>
<tr>
<th>Pathway Name</th>
<th>Matched metabolites</th>
</tr>
</thead>
<tbody>
<tr>
<td>Arginine and proline metabolism</td>
<td>Citrulline; Guanidoacetic acid; N-Acetyl-L-alanine; 4-Guanidinobutanoic acid</td>
</tr>
<tr>
<td>Purine metabolism</td>
<td>Xanthine; Inosine; Uric acid; Adenine</td>
</tr>
<tr>
<td>Lysine degradation</td>
<td>4-Trimethylammoniobutanoic acid; Pipecolic acid</td>
</tr>
<tr>
<td>Cysteine and methionine metabolism</td>
<td>5′-Methylthioadenosine; L-Cystine</td>
</tr>
<tr>
<td>Glycerophospholipid metabolism</td>
<td>Phosphorylcholine; O-Phosphoethanolamine</td>
</tr>
<tr>
<td>Glycine, serine and threonine metabolism</td>
<td>Glyceric acid; Guanidoacetic acid</td>
</tr>
</tbody>
</table>
FIGURE LEGENDS

Figure 1. Knockout of Mocos induces a partial phenotype in mice. (A) Schematic representation of the Mocos disruption strategy using the CRISPR/Cas9 technology. The deletion of exon 3 induces the loss of frame in case of splicing between exon 2 and exon 4 resulting in a truncated non-functional MOCOS protein. (B) Relative Mocos expression was quantified by qPCR; Data were from mice at 4 weeks of age and expressed as means±SEM, **P<0.01. (C) Renal expression and quantification of MOCOS protein by western blot (data were from 4 week-old animals). (D) Frequency distribution of animals of the indicated genotype. The percentages of male (M) and female (F) mice of each genotype are indicated. (E) Phenotypic comparison of wild type+/+, heterozygous Mocos+/− and knockout Mocos−/− mice. Mocos−/− animals are easily distinguished from littermates at 4 weeks because of their lower body size and weight. (F) Body weight of mice at 4 weeks of age. 12 to 17 animals per group were analyzed. Data were expressed as means±SEM, ***P<0.001. (G) Percentage of survival of wild-type (circle, n=168), heterozygote (square, n=239), and Mocos−/− (triangle, n=15) mice in days after birth. (H) Lifespan of Mocos−/− mice (n=15).

Figure 2. Mocos knockout induces obstructive nephropathy. (A) Representative images of whole kidney sections of mice at the age of 4 weeks. KO kidney shows an irregular outer contour due to numerous scars (indentions (arrows) and cystoid tubules (right, H&E stain). Control kidney (left, trichrome stain). By planimetry the size of the KO kidneys was reduced by 50% on average. (B) KO Mouse: prominent interstitial fibrosis (blue staining cortex, trichrome stain and numerous cystoid tubules, mainly cortical collecting ducts (left), subcapsular scar with densely packed glomeruli (encircled), interstitial fibrosis, scanty
interstitial infiltrates. (right, HE stain). (C) Tubulo-interstitial space with dilated tubules, some with polymorphonuclear leukocytes (arrow) or lamellate bodies (uromodulin) (arrowheads), intratubular giant cell (x) and loss of tubular epithelium, (left, HE stain). Right top: lamellate roundish intratubular deposit (stained for uromodulin with immunohistochemistry, brown) note adjacent tubule stuffed full with polymorphonuclear leukocytes. Right bottom: Empty crystal clefts in tubules (arrow), (semithin section stained with methylene blue). (D) Kidney cross-section similar to Fig A an B. Papillary tip and on the opposite side renal pelvis covered by uromodulin (x). The ducts in the papillary tip are highly dilated and contain lamellate bodies. (left, HE stain). Right higher magnification of the pelvic wall: Note damage of the urothelium with denudation (between arrows) off the pelvic smooth muscle wall (arrow). The adjacent urothelium is preserved (U). (magnification in all figures: bar= µm)

Figure 3. Constitutive MOCOS KO mice accumulate xanthine stones. (A) The picture shows representative images of the transparent urine of homozygous Mocos−/− mice compared to the yellow color of urine characterizing wild type and heterozygous Mocos+/- mice. The arrow points to deposits in urine from a Mocos−/− mouse. (B) Measurement of urinary pH in mouse strains. Data were from mice at 4 weeks of age and expressed as means±SEM, **P<0.01. (C) Concentrations of xanthine and hypoxanthine are significantly increased in urine and (D) serum of homozygous Mocos−/− mice compared with age-matched littermate controls. Data were from mice at 4 weeks of age and expressed as means±SEM, *P<0.05, **P<0.01. (E) The picture is an example of xanthine stones from a Mocos−/− mouse. Scale bars: 200 μm. (F) Crystals collected from a Mocos−/− kidney were analyzed by Raman spectroscopy. In these crystals, the strongest bands observed at 542, 653, 960, 1208, 1264, 1330 and 1433cm−1 are considered as marker bands of xanthine (lower green panel) by comparison with a commercial standard (upper blue panel).
Figure 4. *Inactivation of Mocos leads to impaired renal and hepatic functions.* Analysis of serological parameters including (A) creatinine, (B) urea, (C) uric acid, (D) alanine aminotransferase (ALAT), (E) alkaline phosphatase and (F) aspartate aminotransferase (ASAT) from 4 week–old animals. *Mocos*<sup>−/−</sup> mice were compared with heterozygous *Mocos*<sup>+/−</sup> and wild type littermate controls (n= 5 for each genotype). Each bar represents the means ±SEM, *P*< 0.05, **P**< 0.01.

Figure 5. *Mocos*<sup>−/−</sup> mice display anemia. White blood cells counts and differential counts performed to identify the type of leukocytes are given as a percentage. The haematogram of homozygous *Mocos*<sup>−/−</sup> mice was compared with that of littermate controls at 4-week of age. The reference range for each group of parameter is indicated. Data are means±SEM, **P**< 0.01, ***P**< 0.001.

Figure 6. *Mocos* gene disruption induces expression of adipogenesis-related genes, inflammatory response and interstitial fibrosis in *Mocos*<sup>−/−</sup> kidney. (A) Enhanced expression of C/EBP-β and PPARγ in *Mocos* KO mice compared with controls. Transcription was measured by RT-PCR in 4 week-old mice. Data are expressed as means±SEM, *P*< 0.05. (B) Genes involved in inflammatory response were significantly upregulated in *Mocos* KO kidneys when compared with kidneys from littermate controls. Expression levels of TNFα and MCP1/CCL2 were measured by RT-PCR. Data were from mice at 4 weeks of age and expressed as means±SEM, *P*< 0.05, **P**< 0.01. (C) Disruption of the *Mocos* gene induced renal interstitial fibrosis. The expression levels of TGFβ1 and serpine/PAI1 were measured by RT-PCR in 4-week–old mice (n=5 for each genotype). Results are expressed as means±SEM, * P*< 0.05, ** P**< 0.01. (D) TUNEL staining shows apoptosis of tubular epithelial cells in kidneys
from *Mocos*−/− mice (scale bar: 100µm). (E) Immunofluorescence staining of Ki67 revealed markedly increased cell proliferation in kidneys of *Mocos* KO mice at 4-weeks of age when compared to controls. DAPI was used to label nuclei. (F) Quantitation of cell proliferation was determined by counting the number of Ki67 positive nuclei in each mouse strain of the specified genotypes.

**Figure 7. Mocos deletion alters detoxification defenses in kidney.** (A) Disruption of *Mocos* induces decreased expression levels of NOX4 and (B) increased transcription of GCLC but no modification of genes encoding several antioxidant and detoxifying enzymes such as (C) NQO1, (D) GPX1, (E) SOD1 and (F) GLO1 in *Mocos*−/− kidneys when compared to littermate controls. (G-H) The transcription of TXN was not affected but the TXN complex was unbalance with significant upregulation of TXNIP in xanthinuric mice. (I) Expression of TXNDC12 dithiol-disulfide oxidoreductase of the endoplasmic reticulum and (J) AKR1B8, an aldoketoreductase involved in carbonyl detoxification was significantly upregulated in *Mocos*−/− mice but not in wild type and heterozygotes mice. All results were obtained by RT-PCR in kidneys of 4-week–old mice (n=4 to 7 for each genotype). Results were expressed as means±SEM, *P* < 0.05, **P** < 0.01. (K) Renal expression of AKR1C1 is significantly disturbed in *Mocos* KO mice when compared to controls (western blot).

**Figure 8. Metabolome analysis of kidneys from Mocos−/− mice and littermate controls.** Heat map depicting the top 31 most significantly affected metabolites, where red indicates an increase concentration and blue indicates a decrease. Kidneys from young *Mocos*−/− mice (class C) were compared to kidneys from *Mocos*+/− (class B) and wild type littermates (class A) (distance measure using Euclidean, and clustering algorithm using Ward).
Figure 1

A. Mocos gene

Wild type allele: 575 bp
Mutated allele: 332 bp

CRISPR/Cas9 cleavage

B. Relative MOCOS expression

C. Mocos protein level

D. Percentage of animals

E. +/+  +/+  -/-

F. Body weight (g)

G. Percentage of survival

H. Days of life
Figure 2A
Figure 2B
Figure 2D
Figure 3

A

B

C

D

E

F

pH urine

Xanthine stones

Xanthine/Hypoxanthine [nmol/50µL] in urine

Xanthine/Hypoxanthine [nmol/50µL] in serum

Raman shift (cm⁻¹)
Figure 5

- Mean corpuscular hemoglobin (pg)
- Mean corpuscular volume (fl)
- White blood cells
- Lymphocytes (%)
- Monocytes (%)
- Neutrophils (%)
- Eosinophils (%)
- Lymphocytes
- Monocytes
- Neutrophils
- Eosinophils
- Red blood cells
- Mean corpuscular volume
- Hemoglobin
- Mean Corpuscular Hemoglobin Concentration
- Mean corpuscular hemoglobin
Deletion of *Mocos* induces xanthinuria with obstructive nephropathy and major metabolic disorders in mice

Delphine Sedda et al.

**Supplemental Methods**

Histological and Immunofluorescence Analysis

Dissected tissues were fixed in 4% buffered paraformaldehyde and paraffin embedded under standard conditions. Tissue sections (3 μm) were stained with hematoxylin and eosin. The slides were examined blindly by 2 independent investigators with a Nikon microscope (Nikon eclipse 80i; Nikon, Tokyo, Japan) or with stereomicroscope (Leica M80). For Immunofluorescence, tissues were fixed for 3 days in 4% PFA and submerged in 20% sucrose for 1 week. They were then embedded in OCT (Tissue-Teck) and 10 μM sections were prepared with cryotome (Leica). TUNEL staining was performed on sections using the ApopTag® Fluorescein In Situ Apoptosis Detection kit (Merck, S7110) following manufacturer's protocol. For Ki67 (PCNA) staining, slides were incubated 30 min in citrate buffer at 80 °C, washed in TBS-Tween and then incubated overnight with rabbit-anti-mouse-Ki67 (Abcam, 4 μg/ml, ab15580). After washing with slides were treated with 0,05% pontamin sky blue (Sigma) for 15 min and then incubated with secondary goat anti-rabbit antibody (Abcam ,2μg/mL, ab150077) for 45 min at room temperature. After washing, slides were
incubated with DAPI (Fisher Scientific) and mounted in fluoromount® (SouthernBiotech). Tissue sections were analysed on a Leica fluorescence microscope Leica (Leica, CTR6000) at x200 magnification. The slides were analyzed and semi-quantitatively scored.

Metabolic analysis

Metabolic analyses were performed by liquid chromatography coupled with high resolution mass spectrometry (LC-HRMS) based on standard metabolomics approaches. Briefly, frozen kidney tissue samples were lyophilized during 48 h and milled to a fine powder. Two milligrams of ground samples were extracted with 1.5 mL of Methanol/milliQ water (1/1). After centrifugation, the supernatants were collected and concentrated at 35°C for 2h30. The analyses were done on a UPLC Ultimate 3000 system (Dionex), coupled to a Q-Exactive mass spectrometer (Thermo Fisher Scientific, Germany) and operated in positive (ESI+) and negative (ESI−) electro spray ionization modes. Chromatography was carried out with a PhenomenexKinetex1.7mXB C18 (150mm×2.10mm) and 100Å UHPLC column. The solvent system comprised mobile phase A [0.1% (vol/vol) formic acid in water], and mobile phase. Data were processed using Xcalibur® software (Thermo Fisher Scientific, San Jose, CA). A library of standard compounds (Mass Spectroscopy Metabolite Library of Standards MSMLS supplied by IROA TechnologiesTM) were analyzed with the same conditions and gradient of mobile phases than those used to analyze the extracted metabolites. For data processing, briefly, peaks with greater than 30% variance (CV %) in quality control samples were removed. The normalization was done to the total area of the peaks of interest. The multivariate analyses were done using Simca-P+-15 software (Umetrics, Umeå, Sweden) as previously described36. Briefly, the data analyses were first conducted using principal component analysis (PCA) to detect outliers. Discriminant metabolites were obtained after orthogonal partial least squares discriminant analysis (OPLS-DA), after elimination of metabolites with low impact in the
separation of the different groups. The listing of discriminant metabolites [very important in projection (VIP)] is given in supplementary data, Table S1. Univariate analyses were performed as non-parametric tests (Wilcoxon rank-sum test) using the web free server Metaboanalyst (https://www.metaboanalyst.ca/) with an FDR adjusted p-value of 0.05 (see listing of significant metabolites in supplementary data, Table S1). VIP and significant metabolites were introduced in pathways analysis module in MetaboAnalyst. Pathways showing the lowest p-value, with an impact value different from zero were chosen from the pathway topology analysis.

Legends of Supplemental figures

Supplemental Figure 1. Heterozygous Mocos mice develop normally but Mocos KO mice display major morphologic abnormalities in kidney, liver and brain. (A) Body weight evolution in adult heterozygous Mocos mice and wild type littermates of 8, 10 and 12 month of age. (B) Pictures showing the small size and irregular surface of a Mocos⁻/⁻ kidney (by planimetry the size of Mocos⁻/⁻ kidneys are reduced by 50 % on average when compared to controls). (C) Mocos KO mice (n=10) had significantly decreased kidney weights and kidney to body weight ratios, compared with their control littermates at 4 weeks of age (n=6). (D-H) Organ weight and organ/body weight ratio were all assessed in mice at 4 weeks of age. Data are expressed as means ± SEM, *P<0.05, **P<0.01, ***P<0.001.

Supplemental Figure 2. Deletion of Mocos causes occasional hydronephrosis in homozygous mutants surviving until 2 months. H&E staining of kidney sections with highly atrophic parenchymal rim (left
Supplemental Figure 3.

**Mocos disruption does not change the histology of organs except the kidney in young mice.**

H&E staining of (A) liver and (B) lung sections from 4 week-old Mocos<sup>−/−</sup> mice and littermate controls (scale bar: 100µm). (C and D) Staining of kidney sections from 8- and 10 month-old heterozygous Mocos mice compared with wild type littermates. (E and F) Staining of liver sections from 8 and 10 month-old heterozygous Mocos mice compared with wild type controls (scale bar: 100µm).

Supplemental Figure 4.

**Adult heterozygous Mocos mice display no disturbances of renal function.** Analysis of serological parameters including (A) creatinine, (B) urea, (C) uric acid, (D) alanine aminotransferase (ALAT), (E) alkaline phosphatase and (F) aspartate aminotransferase (ASAT). Sera from young and adult Mocos<sup>+</sup> mice were compared with those from littermate control mice. Each bar represents the mean ± SEM.

Supplemental Figure 5.

**Adult heterozygous Mocos mice exhibit normal hematological parameters.** Hematological parameters of Mocos<sup>+</sup> mice were compared with those of wild type mice at 15- and 20- months.

Supplemental Figure 6.

**Clustering result shown as heatmap** for the discriminant metabolites in kidney from the 3 groups of Mocos<sup>+</sup>, Mocos<sup>+/−</sup> and Mocos<sup>−/−</sup> mice.
Supplemental Figure 7

The purine and arginine/nitric oxide pathways in xanthinuric mice. AMP (adenosine monophosphate); IMP (inosine monophosphate); GMP (guanosine monophosphate); NO (nitric oxide); PNP1 (purine nucleoside phosphorylase1); GDA (guanine desaminase); UOX1 (urate oxidase1); OTC (ornithine transcarbamylase); NOS (nitric oxide synthase); ARG1 (arginase1); XOR (Xanthine oxidoreductase); AOX1 (aldehyde oxidase1).

Supplemental Table 1.
List of primers

Supplemental Table 2.
Listing of discriminant metabolites obtained after univariate analysis [Wilcoxon rank-sum test with an FDR adjusted p-value of 0.05, visualized by *) cumulated with VIP discriminant metabolites obtained after OPLS-DA (visualized by √), CV-ANOVA of the model was given in the first row of the table] from kidney tissues analysis of wildtype, Mocos\textsuperscript{+/-} and KO mice.
Supplemental Figure 1

A

Body weight (g)

3 months 10 months 12 months

+/- +/- -/-

0.0 0.1 0.2 0.3

B

+/- +/- -/-

0 1 2 3

**** ***

C

Liver/body weight (%)

+/- +/- -/-

0.0 0.5 1.0 1.5 2.0

**** ****

D

Liver weight (g)

+/- +/- -/-

0 1 2 3

**** ****

E

Brain weight (g)

+/- +/- -/-

0.25 0.30 0.35 0.40 0.45

***

F

Lung weight (g)

+/- +/- -/-

0.0 0.1 0.2

****

G

Spleen weight (g)

+/- +/- -/-

0.00 0.04 0.08

****

H

Intestine weight (g)

+/- +/- -/-

0.0 0.5 1.0

****
Supplemental Figure 2
Supplemental Figure 3

A

B

C

D

E

F

liver

lung

kidney

liver
Supplemental Figure 5

White blood cells in blood (10^3/l)

Lymphocytes in blood (%)

Monocytes in blood (%)

Granulocytes in blood (%)

Eosinophils in blood (%)

Platelets in blood

Red cells in blood

Hemoglobin in blood (g/dl)

Hematocrit in blood (%)

Hematocrit in blood

Eosinophils in blood (%)

Platelets in blood

Red cells in blood

VGM in blood

TCMH in blood

TCMH in blood
Supplemental Figure 6
### Supplemental Table 1

<table>
<thead>
<tr>
<th>Gene</th>
<th>Forward Primer</th>
<th>Reverse Primer</th>
<th>Gene ID</th>
</tr>
</thead>
<tbody>
<tr>
<td>Mocos</td>
<td>(F) 5’-CACCACCGCAGAAGACTACAC-3’</td>
<td>(R) 5’-CACGTTCCGCATACCCACTAC-3’</td>
<td>QT01195936</td>
</tr>
<tr>
<td>TNF-α</td>
<td>(F) 5’-AAGCCTGTAGCCCACGTCGTA-3’</td>
<td>(R) 5’-GGCACCACTAGTTGGTTGTCTTTG-3’</td>
<td>QT00145250</td>
</tr>
<tr>
<td>MCP-1/CCL2</td>
<td>(F) 5’-GCCCCACTACCTGCTGCTACT-3’</td>
<td>(R) 5’-CCTGCTGCTGTTGATCCTTTGT-3’</td>
<td>QT00126042</td>
</tr>
<tr>
<td>Actb</td>
<td>(F) 5’-TCAGCAAGCAGGAGTACGATG-3’</td>
<td>(R) 5’-GGGTGTAAAACGCAGCTCAACAG-3’</td>
<td>QT00154756</td>
</tr>
<tr>
<td>Gpx1</td>
<td></td>
<td></td>
<td>QT00165039</td>
</tr>
<tr>
<td>Tgfβ</td>
<td></td>
<td></td>
<td>QT00198443</td>
</tr>
<tr>
<td>Nox4</td>
<td></td>
<td></td>
<td>QT00296513</td>
</tr>
<tr>
<td>Serpine1</td>
<td></td>
<td></td>
<td>QT01060297</td>
</tr>
<tr>
<td>Sod1</td>
<td></td>
<td></td>
<td>QT00094367</td>
</tr>
<tr>
<td>Tbp</td>
<td></td>
<td></td>
<td>QT0141834</td>
</tr>
<tr>
<td>Gclc</td>
<td></td>
<td></td>
<td>QT01141834</td>
</tr>
<tr>
<td>Nqo1</td>
<td></td>
<td></td>
<td>QT00130543</td>
</tr>
<tr>
<td>Txn1</td>
<td></td>
<td></td>
<td>QT01060297</td>
</tr>
<tr>
<td>Txnip</td>
<td></td>
<td></td>
<td>QT00296513</td>
</tr>
<tr>
<td>Txndc12</td>
<td></td>
<td></td>
<td>QT00141834</td>
</tr>
<tr>
<td>Gene</td>
<td>Accession</td>
<td></td>
<td></td>
</tr>
<tr>
<td>-------</td>
<td>------------</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Akr1b8</td>
<td>QT00107800</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Cebpb</td>
<td>QT00320313</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Pparg</td>
<td>QT00100296</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Supplemental Table 2

<table>
<thead>
<tr>
<th>Metabolite</th>
<th>+/- vs +/−</th>
<th>+/- vs +/-</th>
<th>+/- vs -/-</th>
<th>+/- vs +/- vs -/-</th>
</tr>
</thead>
<tbody>
<tr>
<td>OPLS-DA CV-ANOVA</td>
<td>0.15</td>
<td>9e-012</td>
<td>1e-010</td>
<td>0.12</td>
</tr>
<tr>
<td>1-OLEOYL-GLYCEROL</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>2-DEOXY-D-GLUCOSE</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-AMINOCHLOROBUTANOATE</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>4-AMINOBUTANOATE</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-HYDROXY-GLYCIDOACETATE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>5-HYDROXYLYSINE</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>5-METHYLTHIOADENOSINE</td>
<td>*</td>
<td>*</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>ADENINE</td>
<td></td>
<td>*</td>
<td>*</td>
<td>*</td>
</tr>
<tr>
<td>ALLANTOIN</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>ALPHA-AMINOADIPATE</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CITRULLINE</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>CREATININE</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>DEOXYCARNITINE</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>ETHANOLAMINE PHOSPHATE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>ETHYLMALONIC ACID</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>FORMYL-L-METHIONYL PEPTIDE</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>GALACTITOL</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>GLYCERATE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>GUANIDINOACETATE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>INOSINE</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-CARNITINE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>L-CYSTEIC ACID</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>L-CYSTINE</td>
<td></td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>L-PIPECOLIC ACID</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>MALATE</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>MANNITOL</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>MANNITOL</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>N-ACETYL-ALANINE</td>
<td>*</td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-ACETYL-GLUTAMIC ACID</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>N-ACETYL-LYSINE</td>
<td>*</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>N-ACETYL-METHIONINE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>N-AMIDINO-ASPARTATE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>NICOTINAMIDE MONONUCLEOTIDE</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PANTOTHENIC ACID</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>PHOSPHOCHOLINE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>PURINE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>SUCCINATE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>THYMINE</td>
<td></td>
<td>*</td>
<td></td>
<td></td>
</tr>
<tr>
<td>TRIGONELLINE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>Metabolite</td>
<td>*</td>
<td>√</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>----------------------------</td>
<td>---</td>
<td>---</td>
<td>---</td>
<td></td>
</tr>
<tr>
<td>URACIL-5-CARBOXYLIC ACID</td>
<td>*</td>
<td>√</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>URATE</td>
<td>√</td>
<td>√</td>
<td>*</td>
<td></td>
</tr>
<tr>
<td>XANTHINE</td>
<td>*</td>
<td></td>
<td>*</td>
<td></td>
</tr>
</tbody>
</table>

Listing of discriminant metabolites obtained after univariate analysis [Wilcoxon rank-sum test with an FDR adjusted p-value of 0.05, visualized by *) cumulated with VIP discriminant metabolites obtained after OPLS-DA (visualized by √), CV-ANOVA of the model was given in the first row of the table] from kidney tissues analysis of wildtype, Mocos<sup>+/−</sup> and KO mice.